Whole blood platelet function assay on the ICHOR(TM) point-of-care hematology analyzer

Journal of Extra-Corporeal Technology

Volumn 30, Issue 4, 1998, Pages 171-177

  Carville, David G M ^a,b   Schleckser, Patricia A ^b   Guyer, Kirk E ^a   Corsello, Michael ^b   Walsh, Mark M ^c  

^a INDIANA UNIVERSITY SOUTH BEND   (United States)

^b Array Medical   (United States)

^c St Joseph's Medical Center   (United States)

Author keywords

Cardiopulmonary bypass; Platelet function; Point of care; Whole blood

Indexed keywords

ANALYZER; ARTICLE; CARDIOPULMONARY BYPASS; HEART CATHETERIZATION; HEMATOLOGY; HEMOSTASIS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0032468965     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders 1992:1-16.
2. Badimon L, Badimon JJ, Fuster V. Pathogenesis of thrombosis. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders 1992:17-39.
3. Despotis GJ, Levine VL, Goodnough LT. Relationship between leukocyte count and patient risk for excessive blood loss after cardiac surgery. Crit Care Med. 1997; 25: 1338-1346.
4. Sughayer M, Arkin CF. Monitoring coagulation during and after cardiopulmonary bypass surgery. Thromb Hemost. 1990; 12: 1-7.
5. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass: Review. Blood. 1990; 76: 1680-1697.
6. Khuri SF, Wolfe JA, Josa M, et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg. 1992; 104: 94-107.
7. Despotis GJ, Santoro SA, Spitznagel E. et al. Prospective evaluation and clinical utility of on-site monitoring of patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1994; 107: 271-279.
8. De Wood MA, Spores J, Notscke R. et al. Prevalence of total coronary occlusion during the earh hours of transmural myocardial infarction. N Engl J Med. 1980; 303: 897-905.
9. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation. 1997; 95: 614-617.
10. Califf RA, Willerson JT. Percutaneous transluminal coronary angioplasty: prevention of occlusion and restenosis. In: Fuster V, Verstraete M. eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders 1992; 389-408.
11. Anderson HV, Jordan RE, Weisman HF. Concept and clinical application of platelets glycoprotein IIb/IIIa inhibition with abciximab (c7E3 Fab; ReoPro) for the prevention of acute ischemic syndromes.
12. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994; 308: 81-91.
13. Coller BS. A new murine monoclonal antibody reports on activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985; 76: 101-108.
14. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC) trial. Am J Cardiol. 1995; 75: 559-562.
15. Moditerno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonist and thrombolytic therapy for acute myocardial information. Thromb Haem. 1997; 78: 214-219.
16. Schwartz L, Bourassa MG, Lesperance L, et al. Aspirin and dypridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988; 318: 1714-1719.
17. Tcheng JE. Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trial in interventional cardiology. Thromb Haem. 1997; 78: 205-209.
18. Plow EF, Ginsberg MH. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb. 1988; 9: 117-156.
19. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIa integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty. Circulation 1994; 90: 1757-1764.
20. Simoons ML, de Boer MJ, van der Brand MJBM, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
21. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose weight adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol. 1997; 79: 286-291.
22. Ogilby JD, Carville DGM. Anticoagulant management in interventional cardiology (monitoring heparin using the activated clotting time instrumentation). Cardio Rev Reports. 1998; November: 34-47.
23. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol. 1963; 168: 178-195.
24. Born GVR, Hardisty RM. Platelets. In: Biggs R, ed. Human blood coagulation haemostasis and thrombosis, 2nd Ed. London: Blackwell Scientific Publications. 1976; 168-201.
25. Dawicki DD, Argawal KC, Parks RE. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep, and nitrobenzylthioinosine. Biochem Pharmacol. 1985; 34: 3965-3972.
26. TM. Platelet function analyzer. Technical information. 1997.
27. Ray MJ, Hawson GAT, Just SJE, McLachlan G. O'Brien M. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. Ann Thorac Surg. 1994; 57: 981-986.
28. Bachmann F, McKenna R, Cole ER, Najafi H. The hemostatic mechanism after open heart surgery. I: Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. J Thorac Cardiovasc Surg. 1975; 70: 76-85.
29. Campbell FW, Addonzio VP. Platelet function alterations during cardiac surgery. In: Ellison N, Jobes DR, eds. Effective hemostasis in cardiac surgery, 1st Ed. Philadelphia: WB Saunders, 1988: 85-109.
30. Riess H, Braun G, Brehm G, Hiller E. Critical evaluation of platelet aggregation in whole human blood.
31. Podczasy JJ, Lee J, Vucenik I. Evaluation of whole-blood lumiaggregation. Clin Appl Thromb/Hemost. 1997; 3: 190-195.
32. National Institutes of Health Consensus Conference. Platelet transfusion therapy. JAMA. 1987; 257: 1777-1780.